Ziaei Hezarjaribi Hajar, Toluee Elahe, Saberi Reza, Dadi Moghadam Yousef, Fakhar Mahdi, Akhtari Javad
Department of Parasitology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Parasitology, Toxoplasmosis Research Center, Communicable Diseases Institute, School of Medicine, Mazandaran University of Medical Sciences, PO Box 48471-91971, Sari, Iran.
J Parasit Dis. 2021 Dec;45(4):921-929. doi: 10.1007/s12639-021-01380-3. Epub 2021 Mar 25.
keratitis (AK) is a rare but serious infection of the eye and can lead to blindness. The effective and safe medical therapy remains unclear for AK until present. Antimicrobial activity and biological characteristic of chitosan encourage screening of it against . Thus, in vitro anti-amoebic activities of commercial chitosan and nano-chitosan were tested on pathogenic genotype T4, a causative agent of human AK. The spp. was isolated from the keratitis patient The genotype T4 was approved using PCR method followed by sequencing technique. Chitosan nanoparticles was prepared using ionic gelation method and characterized by their physicochemical properties. In the present study, the in vitro activity of serial dilutions (12.5, 25, 50, 100, and 200 µL/mL) of commercial chitosan and nano-chitosan were evaluated against trophozoites and cysts. The finding of nano-chitosan particle size by DLS was 118 nm with a PDI of about 0.134. Zeta potential value was found to be 42.7 mV. The obtained results showed that the tested chitosan and nano-chitosan presented anti-amoebic activities dependent to time and concentration. The inhibitory effect of the chitosan and nano-chitosan is enhanced by increasing the concentration and incubation time. The inhibitory effect of nano-chitosan on both trophozoites and cyst was more than chitosan. According to the results, nano-chitosan shows the potent activity against T4 and could be used for the development of novel and safe therapeutic approaches in the future.
棘阿米巴角膜炎(AK)是一种罕见但严重的眼部感染,可导致失明。直到目前,针对AK的有效且安全的药物治疗仍不明确。壳聚糖的抗菌活性和生物学特性促使人们对其进行抗棘阿米巴的筛选。因此,对市售壳聚糖和纳米壳聚糖针对人AK病原体基因型T4进行了体外抗阿米巴活性测试。该棘阿米巴属菌株从角膜炎患者中分离得到,采用聚合酶链反应(PCR)方法并结合测序技术鉴定出基因型T4。采用离子凝胶法制备壳聚糖纳米颗粒,并对其理化性质进行表征。在本研究中,评估了市售壳聚糖和纳米壳聚糖系列稀释液(12.5、25、50、100和200µL/mL)对棘阿米巴滋养体和包囊的体外活性。通过动态光散射(DLS)测定纳米壳聚糖的粒径为118nm,多分散指数(PDI)约为0.134。测得的ζ电位值为42.7mV。所得结果表明,所测试的壳聚糖和纳米壳聚糖呈现出依赖于时间和浓度的抗阿米巴活性。壳聚糖和纳米壳聚糖的抑制作用随浓度和孵育时间的增加而增强。纳米壳聚糖对滋养体和包囊的抑制作用均强于壳聚糖。根据结果,纳米壳聚糖对棘阿米巴T4显示出强效活性,未来可用于开发新型安全的治疗方法。